Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Breast Neoplasms 11Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Patient Preference 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Communication 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Nivolumab 2Cyclophosphamide 2tislelizumab 1spartalizumab 1pembrolizumab 1montanide ISA 51 1glembatumumab vedotin 1fludarabine phosphate 1entinostat 1cemiplimab 1Toll-Like Receptor 1 1Surveys and Questionnaires 1Specimen Handling 1Rose Bengal 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Interleukin-13 1Focus Groups 1Fluorodeoxyglucose F18 1Cryosurgery 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Focus Groups × Breast × Clear all
NCT04118062 2025-09-19

Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)

Institut Curie

Phase NA Completed
128 enrolled
BreastDermatologic

Uveal Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡